Urolume endourethral prosthesis for the treatment of urethral stricture disease: long-term results of the North American Multicenter UroLume Trial.
OBJECTIVE
To evaluate the long-term results of the UroLume endourethral prosthesis for the treatment of recurrent bulbar urethral strictures.


METHODS
In a multicenter, prospective study 175 patients with recurrent bulbar urethral strictures were enrolled in a Food and Drug Administration (FDA) trial of the UroLume endourethral prosthesis. One hundred thirty-nine patients were available for follow-up at 1 year, and 81 patients were available for follow-up at 2 years.


RESULTS
Clinically and statistically significant results were seen at 1 year and sustained at 2 years. Re-treatment rate was down from 75.2% preinsertion to 14.3% 1 year postinsertion of the prosthesis. Explantation was required in only 3% of patients.


CONCLUSIONS
Based on these and European data, the UroLume endourethral prosthesis offers a significant advantage over the currently available treatments for recurrent bulbar urethral strictures.
Badlani
G H
GH
Department of Urology, Long Island Jewish Medical Center, New Hyde Park, New York, USA.
Press
S M
SM
Defalco
A
A
Oesterling
J E
JE
Smith
A D
AD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002170:Canada; D019723:Endoscopes; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D011446:Prospective Studies; D019736:Prostheses and Implants; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012008:Recurrence; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014525:Urethral Stricture / Q000503:physiopathology / Q000601:surgery*; D014563:Urodynamics